Cargando…
Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells
Drug repurposing is a cost-effective means of targeting new therapies for cancer. We have examined the effects of the repurposed drugs, bezafibrate, medroxyprogesterone acetate and valproic acid on human osteosarcoma cells, i.e., SAOS2 and MG63 compared with their normal cell counterparts, i.e. mese...
Autores principales: | Sheard, Jonathan J., Southam, Andrew D., MacKay, Hannah L., Ellington, Max A., Snow, Martyn D., Khanim, Farhat L., Bunce, Christopher M., Johnson, William E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786328/ https://www.ncbi.nlm.nih.gov/pubmed/33289496 http://dx.doi.org/10.1042/BSR20202505 |
Ejemplares similares
-
Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia
por: Khanim, Farhat L., et al.
Publicado: (2009) -
Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers
por: Murray, Jim, et al.
Publicado: (2019) -
Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing
por: Jiang, Yao, et al.
Publicado: (2021) -
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate
por: Khanim, F, et al.
Publicado: (2014) -
Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate
por: Yuasa-Shibasaki, Erina, et al.
Publicado: (2017)